Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC sunscreens rule

This article was originally published in The Tan Sheet

Executive Summary

FDA will continue to accept comments on its proposed rule to amend the final monograph for over-the-counter sunscreen products until Dec. 26, the agency announces in a Nov. 28 Federal Register notice. The agency pushed the deadline back by one month in response to requests from parties wanting additional time to submit comments. FDA issued the proposed rule Aug. 23, amending the final monograph to include UVA ray protection standards including in vivo and in vitro tests (1"The Tan Sheet" Aug. 27, 2007, p. 3). The final monograph was issued in 1999, but has consistently been stayed due to pressure from industry...

You may also be interested in...



Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity

FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.

Topics

UsernamePublicRestriction

Register

PS101160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel